<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00329472</url>
  </required_header>
  <id_info>
    <org_study_id>2004-09-027</org_study_id>
    <nct_id>NCT00329472</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer</brief_title>
  <official_title>Randomized Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Plus Adjuvant Chemotherapy Versus Surgery Plus Adjuvant Chemotherapy in Stage IB, IIA, IIB and T3N1 Non-small Cell Lung Cancer (ICON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      This study is randomized phase III trial designed to assess whether (preoperative)
      neoadjuvant chemotherapy followed by surgery plus adjuvant chemotherapy with gemcitabine and
      cisplatin (experimental treatment) improves 3-year disease-free survival, compared to surgery
      plus adjuvant chemotherapy with gemcitabine and cisplatin (standard treatment) in stage IB,
      IIA, IIB and T3N1 non-small cell lung cancer
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    poor enrollment
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pattern of relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative mortality and toxicity</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Gem/Cis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 &amp; cisplatin 70mg/m2 , 2 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine, cisplatin</intervention_name>
    <arm_group_label>Gem/Cis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven NSCLC patients

          -  All patients must have:Clinical stage IB, IIA, IIB and T3N1 by mediastinoscopy, Chest
             CT and PET-CT

          -  18 year of ages or older

          -  ECOG performance status 0-1

          -  Uni-dimensionally measurable lesion by RECIST criteria

          -  No prior chemotherapy or radiotherapy for NSCLC

          -  Pre-operative FEV1 ≥ 2.0 L evaluated within 28 days

          -  Adequate bone marrow function: Hb &gt; 9.0 g/dL, WBC ≥ 4,000/μL, platelet count ≥
             100,000/μL

          -  Adequate liver and renal function: Total bilirubin &lt; 2 x ULN, AST/ALT &lt; 3 x ULN, serum
             creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 60 mL/min

          -  Written informed consent

        Exclusion Criteria:

          -  Superior sulcus tumor

          -  Prior malignancy except for adequately treated basal cell or squamous cell skin cancer
             or in situ cervical cancer at least 5 years

          -  Uncontrolled systemic illness such as DM, CHF, unstable angina or arrhythmia

          -  Recent myocardial infarction within 6 months

          -  Patients with post-obstructive pneumonia or serious infection

          -  Pregnant or nursing women (Women of reproductive potential have to agree to use an
             effective contraceptive method.)

          -  Patients with psychological problem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keunchil Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2006</study_first_submitted>
  <study_first_submitted_qc>May 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2006</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Keunchil Park/Professor</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

